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Several studies have shown that allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR1) of AML reduces risk of relapse and improves relapse-free survival in intermediate-and poor-risk AML. 1 Benefits in (overall) survival are less obvious. [1] [2] One possible explanation is that after relapse previous receipt of allogeneic HCT in CR1 is associated with shorter survival, with a lower CR rate following therapy for relapse (salvage therapy) a possible contributing factor. Breems et al. reported that in 667 adults age < 60, HCT in CR1 was independently associated with shorter survival after subsequent relapse, with 58 patients receiving allogeneic and 102 autologous HCT. 3 Second CR rate was 33% if HCT had been done in CR1 and 49% if it had not. Burnett et al. noted that survival after relapse was shorter in their 1,064 patients receiving HCT in CR1 than in patients not transplanted in CR1; 23% of the 1,064 patients received autologous HCT and CR rates in the 1,064 were not reported. 4 The aims of our study were to analyze the effect of, specifically, allogeneic HCT in CR1 on the probabilities of (a) achieving second CR (CR2) with first salvage therapy, and (b) survival from first salvage.
We identified 173 consecutive patients with AML (APL excepted) or MDS with 10-19% blasts who after achieving CR1 (< 5% morphologic blasts in marrow, ANC > 1,000 and platelets > 100,000 micro/L) with initial treatment relapsed (> 5% blasts in marrow and/or blood unrelated to recovery of blood counts) between 2008 and 2013 at our center. 161 of the 173 received first salvage therapy. In these 161, we collected data on: (1) age, (2) secondary vs. de novo AML, (3) CR1 duration, (4) number of initial induction courses, (5) number of post-remission courses, (6) ECOG performance status at relapse, (7) cytogenetic category (ELN criteria for adverse, intermediate, "favorable", and "missing" 5 ) at relapse, (8) FLT3 ITD and NPM1 status at relapse, (9) allogeneic HCT in CR1 (yes vs. no, and then myeloablative (MA) vs. reduced intensity (RI) vs. none), (10) intensity of first salvage therapy and (11) HCT in CR2. Cytarabine at ≥ 1 g/m2/dose +/-other drugs or allogeneic HCT were considered "high intensity", "3+7" +/-other drugs as average intensity, and other salvage treatments (typically low-dose cytarabine, or azacitidine) as low intensity. First salvage regimens were chosen informally by attending physicians as were post-remission regimens which included HiDAC, repeats of initial treatment or allogeneic HCT.
45/161 (28%) of patients received HCT in CR1, with 26 given a MA and 19 RI HCT. In 60 of the 116 patients who did not receive HCT in CR1 the decision seemed based on either (a) lack of a matched sibling or unrelated donor, (b) relatively low risk of relapse given "favorable" cytogenetics or NPM1 positive/FLT3 ITD negative status, (c) relative high risk of non-relapse mortality based on age > 75 or HCT co-morbidity index 2-5, or (d) in 28 patients relapse discovered at the pre-HCT evaluation. The reasons for the decision not to proceed to HCT were unclear in almost half the patients (56/116) who did not receive HCT in CR1.
Survival was measured from date of first salvage therapy and analyzed using log-rank tests. Univariate logistic (for CR2 after relapse) and Cox regression (for survival) analyses were performed for the covariates noted above with HCT in CR2 treated as time-dependent covariate. Variables among those noted in the 2nd paragraph above significant at p < 0.10 in univariate analyses were included in multivariable logistic and Cox regression models. The study was approved by the relevant Institutional Review Boards and conducted in accordance with the Declaration of Helsinki. Table 1 shows patient characteristics. MA patients were the youngest and RI patients the oldest (p < 0.001). Since they often were in relapse at pre-HCT evaluation, no-HCT patients had shorter CR1 durations than the MA or RI groups (p < 0.001) but received more post-remission courses. Perhaps reflecting their older age RI patients tended to have poorer performance status and to less often receive intensive therapy at relapse. The CR2 rate with first salvage therapy was essentially similar in the 3 groups: 43/116 (37%) for no-HCT, 11/26 (42%) for MA, and 8/19 (42%) for RI. 50/116 patients in the no-HCT in CR1 group received HCT after first relapse; half the time this was done in CR2 (25/50). Only 9/45 patients who received HCT in CR1 also received HCT after relapse; in 5 patients HCT was done in CR2 (5/9). Paralleling the similar CR2 rates, survival after first salvage was largely identical in the 3 groups ( Figure 1 , p = 0.86), with medians of 8 months for no-HCT and MA, and 6 months for RI.
As expected, univariate analyses indicated that the principal predictor of CR2 achievement was longer CR1 duration (OR 1.03, p = 0.01). Receipt of average or high, rather than low, intensity salvage was also associated (OR 2.5, p = 0.04). Both these covariates were associated with longer survival after first salvage, (HR 0.99, p = 0.06, HR 0.62, p = 0.04) respectively. However the major predictor of longer survival after first salvage was HCT in CR2 vs. no-HCT in CR2 (HR 0.42, p = 0.008).
Multivariable analyses (Tables 2 A-B)
showed that HCT in CR1 had no significant effect on CR2 rate (OR 1.5, p = 0.35) or OS (HR 0.79, p = 0.34). In contrast, CR1 duration, cytogenetics, and performance status, at relapse were independently associated with these outcomes. An analysis of MA vs. RI vs. no-HCT led to similar conclusions (Supplemental Tables 1-2) , as did an analysis of low intensity salvage vs. average-or high-intensity (Supplemental Tables 3-4) . Of particular note the multivariate analyses suggested that if anything the effect of HCT in CR1 on both CR2 (OR 1.50) and OS (HR 0.79) was favorable. Although not statistically significant, it thus seems unlikely that the effect of HCT in CR1 was unfavorable. Furthermore, patients receiving HCT in CR1 did not have poorer OS, although HCT in CR2, which was strongly associated with survival from first salvage, was essentially restricted to patients who did not have HCT in CR1.
The differences between our findings and Breems et al.'s may reflect different practices after relapse. A higher proportion of our patients than Breems et al.'s received first salvage: 93% vs. 81%. Because we were interested in CR2 rate we included only the 161 patients who were treated in our survival analysis while Breems et al. included all relapsed patients. 91% of the patients treated by Breems et al. received intensive salvage therapy including 36% given an allogeneic or autologous transplant. In contrast 53% of our patients received high intensity first salvage (with only 2% receiving allogeneic HCT as first salvage therapy) and with 29% receiving low intensity salvage. While suggesting that a deleterious effect of HCT in CR1 on outcome of salvage therapy might be limited to patients receiving intense salvage therapy, we could not, within the limits of our patient numbers, identify an interaction between effect of each type of HCT in CR1 and intensity of salvage therapy. Breems et al.'s patients were age < 60 (median age approximately 45), and more often received autologous than allogeneic HCT in CR1 (although they did not separately assess the risks of each type of HCT), while our patients were older (median age 53) and only received allogeneic HCT. Burnett et al.'s patients were all age < 50 with 23% receiving autologous HCT. The proportion of patients receiving HCT beyond first relapse was similar in our study and that of Breems et al. (37% vs. 33%) as was the proportion of patients receiving HCT beyond first relapse after not receiving previous HCT in our study and Burnett et al.'s (each 43%). Nonetheless our study was smaller than Breem et al.'s and Burnett et al.'s, and like these studies could have been affected by various selection biases, even after accounting for a relatively large number of covariates (paragraph 2). For example the reason for no-HCT in CR1 was unclear in almost half our patients. While, optimally, the effect of HCT in CR1 on outcome after relapse would be addressed via a trial randomizing patients in CR1 between immediate HCT and HCT only should relapse occur such a trial is unlikely to be done given such biases. With these constraints our results suggest that the effect of HCT in CR1 can be relatively small, and certainly less than those of CR1 duration, cytogenetics and performance status.
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